Advertisement
Bionovo's poster presentation will describe the pathway for cancer cellapoptosis (cell death) induced by BN108. As explained by Dr. Emma Shtivelman,Director of Cancer Research at Bionovo, BN108 induces death in cancer cellsbut not in normal cells. BN108 induces apoptosis through induction of stressin the endoplasmic reticulum. Laboratory studies show that BN108 inhibitsmajor oncogenic pathways, and therefore, can be used for many differentcancers.
Advertisement
"BN108 mechanism of action and unique selective properties are a result ofsome of the distinct biological differences between cancer cells and normalcells. We believe BN108 will result in better selectivity to various cancerswith no collateral damage to normal tissues. BN108 is designed to be an oraldrug candidate that will provide a chronic treatment option with a lowtoxicity profile," said Dr. Isaac Cohen, Chairman and CEO of Bionovo,
Bionovo, Inc.
Bionovo is a pharmaceutical company focused on the discovery anddevelopment of safe and effective treatments for women's health and cancer,markets with significant unmet needs and billions in potential annual revenue.The company applies its expertise in the biology of menopause and cancer todesign new drugs derived from botanical sources which have novel mechanisms ofaction. Based on the results of early and mid-stage clinical trials, Bionovobelieves they have discovered new classes of drug candidates within their richpipeline with the potential to be leaders in their markets. Bionovo isheadquartered in Emeryville, California and is traded on the NASDAQ CapitalMarket under the symbol, "BNVI". For more information about Bionovo and itsprograms, visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to thebusiness of Bionovo, Inc. that can be identified by the use of forward-lookingterminology such as "believes," "expects," or similar expressions. Suchforward-looking statements involve known and unknown risks and uncertainties,including uncertainties relating to product development, efficacy and safety,regulatory actions or delays, the ability to obtain or maintain patent orother proprietary intellectual property protection, market acceptance,physician acceptance, third party reimbursement, future capital requirements,competition in general and other factors that may cause actual results to bematerially different from those described herein as anticipated, believed,estimated or expected. Certain of these risks and uncertainties are or will bedescribed in greater detail in our filings with the Securities and ExchangeCommission, which are available at http://www.sec.gov. Bionovo, Inc. is underno obligation (and expressly disclaims any such obligation) to update or alterits forward-looking statements whether as a result of new information, futureevents or otherwise.
SOURCE Bionovo, Inc.
